SBFM

SBFM

USD

Sunshine Biopharma Inc. Common Stock

$1.730+0.080 (4.848%)

即時價格

Healthcare
Drug Manufacturers - Specialty & Generic
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$1.650

最高

$1.730

最低

$1.650

交易量

0.07M

公司基本面

市值

8.5M

行業

Drug Manufacturers - Specialty & Generic

國家

United States

交易統計

平均交易量

0.73M

交易所

NCM

貨幣

USD

52週範圍

最低 $1.169當前 $1.730最高 $3.9

相關新聞

AccessWire

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma is quickly establishing which side of that line it's on. After

查看更多
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
AccessWire

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Sunshine Biopharma Inc. , a leading pharmaceutical company focused on innovative and affordable healthcare solutions,

查看更多
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea
AccessWire

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma is quietly engineering a flywheel model for biotech. Not a flashy one that spins fast and burns energy and cash quickly. A lean

查看更多
Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)
AccessWire

Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma is the kind of company that keeps the market honest. On paper, it's small, barely a rounding error next to the giants of

查看更多
Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)
Analyst Upgrades

Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target

Aegis Capital analyst David Bouchey reiterates Sunshine Biopharma with a Buy and maintains $7 price target.

查看更多
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target